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ABSTRACT  
Background/Aim: Intermittent claudication (IC) due to peripheral arterial disease (PAD) 
decreases individuals’ capacity to engage in physical activity. Identifying effective 
components of pain management interventions in this population will be of potential value 
because pain is the main symptom limiting physical activity participation. This review will 
assess the components of pain management intervention that improve PA in patients with IC.  
 
Methods: CINAHL, Cochrane Library, Ovid, ProQuest, AMED, MEDLINE, PsycINFO, 
Web of Science Core Collection, ScienceDirect, and PEDRO databases as well as grey 
literature will be searched until January 2016. Studies that investigated the effect of pain 
management interventions in patients with IC, or studies that investigated patients’ 
perceptions to or experience with this intervention will be included. Papers will be screened 
by two authors to identify eligible studies and to assess study quality. Homogenous 
quantitative outcome data will be analysed using a random effects model of meta-analysis 
with results presented as relative risk for dichotomous outcomes and weighted mean or 
standardised mean for continuous outcomes. Qualitative data will be analysed using thematic 
synthesis.  
Expected outcome: The systematic review will make recommendation on the effective 
components of pain management interventions to improve the physical activity of individuals 
with IC. This will guide the development of future interventions using the components 




Peripheral Arterial Disease (PAD) is a clinical manifestation of atherosclerosis, and most 
commonly presents with a symptom of intermittent claudication (IC).  IC, defined as exertion 
related ischaemic pain in the lower limb(s) experienced during walking and relieved by rest, 
is a debilitating condition which limits individuals’ ability to walk and perform personal, 
social and occupational activities of daily life [2-4]. This is reported to affect 4.5% of all men 
and women aged 55-74 years [1]. The implications are that patients with IC suffer mobility 
impairment and loss of control [6], with a consequent decrease in health status, quality of life 
[2-5], and loss of social functions [6].  Additionally, the resultant decreased ability to engage 
in physical activity potentially leads to a further increase in the risk of cardiovascular events 
in a vascular system already compromised by PAD. Current epidemiological reports show 
PAD prevalence has increased by 13% in the last decade [7]. 
Despite the fact that pain has been identified as a key barrier to walking in IC [8], research 
into the effect of analgesic interventions for IC has remained largely inconclusive. Although 
some evidence supports the use of antiplatelet therapy [9-11], there are inconsistencies and a 
lack of clinically worthwhile efficacy in many other reports [12-16]. Transcutaneous 
Electrical Nerve Stimulation (TENS) is an electrotherapeutic modality commonly used in 
physiotherapy to manage pain. TENS is believed to accomplish pain reduction by stimulating 
the large non-nociceptive afferent (Aß) fibres leading to pain gating [17]. Despite the fact that 
TENS is inexpensive, safe, has minimal side-effects, and can be used by patients without 
supervision [18], there is minimal literature that investigates the use of TENS in individuals 
with IC. Seenan et al. demonstrated that TENS, specifically High Frequency-TENS, reduced 
lower limb ischaemic pain in healthy volunteers [19] and increased the walking performance 
of patients with IC in laboratory settings [20]. But whether improved walking capacity could 
be translated into free-living walking, described as “the level of walking that the individuals, 
  
within their physical limitations, at their own pace, and in their own environment, typically 
perform” [21], has yet to be demonstrated.  
Generally, conservative non-operative therapies that target pain relief, and which could be 
implemented in a clinical setting have been identified [20,22]. This, perhaps, makes it 
possible to identify an intervention, a modality or a combination that could be applied to 
relieve pain and increase physical activity in individuals with IC. However, differences in 
intervention setting (hospital vs home/community based), study design (RCTs vs non-RCTs), 
and intervention type, among other factors, may influence the success of an intervention. To 
date, evidence from non-operative pain management interventions targeting physical activity 
improvement among patients with IC has not been systematically evaluated. Therefore, there 
is currently no consensus regarding interventions centred on this pain management to 
improve  physical activity in patients with IC. To develop a potentially effective intervention 
in pain management targeted at improving physical activity, a clear understanding of the 
components required for effectiveness and/or optimum patients’ adherence to these 
interventions is needed. A systematic review of the literature is warranted to explore both 
quantitative and qualitative research evidence and determine the effective components of pain 
management interventions for improving physical activity for patients with PAD and IC.  
The proposed review will mainly seek to address the question of “what constitutes the 
effective components of pain management interventions to improve physical activity in 
patients with IC based on reports from published literature?”. To achieve this, two secondary 
research questions relating to effectiveness of pain management interventions in patients with 
IC?”, as well as patient experiences and perceptions to these interventions need to be 
investigated. This article details the protocol for a systematic review that aims to determine 
the effective components of non-operative pain management for improving physical activity 
in patients with PAD and IC. Specific objectives will include: 1) To determine effectiveness 
  
of pain management interventions in patients with IC, and 2) To investigate experiences or 
perspectives to pain management interventions in patients with IC.  The protocol for this 
systematic mixed studies review will be described according to the Preferred Reporting Items 




The protocol for this review has been registered with the International Prospective Register of 
Systematic Reviews (PROSPERO, CRD42015027912).  The review method will use a two 
stage mixed studies review design. Studies meeting prior broad eligibility criteria will be 
included in the review and described in stage one. Then, stage two will involve further review 
of studies meeting narrower criteria, potentially pooling their data for a meta-analysis. 
Eligibility Criteria  
Decisions regarding eligibility of studies for inclusion in this review are described in terms of 
types of participants, types of study, intervention types, and types of outcomes in studies in 
line with PRISMA-P guideline. These criteria are based on literatures related to diagnostic  
for IC [2-4], as well as adaptation of inclusion criteria from previous reviews on other forms 
of interventions in individuals with intermittent claudication [25,26].  
Types of participants 
Studies involving adults of ≥18 years old participants with PAD and IC will be included. The 
review criteria will exclude participants without symptomatic IC. The basis for the diagnosis 
of IC may be objective, by use of questionnaire or clinically if objective measures were not 
used or reported. Either an ankle brachial index (ABI) < 0.9 or evidence of PAD on Doppler 
ultrasound or angiography will be judged sufficient for objective diagnoses of IC    . No 
particular restrictions will be considered regarding settings of studies to be included. 
  
Therefore, studies conducted in health centres, clinics, hospitals or community settings will 
be included. 
 
Types of studies 
Original research manuscripts in the English language, published in peer review journals, and 
conference proceedings will be included. There will be no restrictions on the types of study 
design eligible for inclusion. Accordingly both RCTs and non-RCTs will be included as long 
as they included at least one of these objectives: evaluated the effects of pain management in 
patients with IC; investigated the factors that influence adherence to these interventions; or 
the factors that influence the effectiveness of the interventions; evaluated patient experiences 
or perceptions of these interventions. Any type of control will be included, as well as pretest-
posttest studies without a control. Both feasibility and pilot studies will be included. Also 
both studies published as full length article or abstract will be included. In all cases effort will 
be made to get data in a form that will enable analyses if not provided in the original 
publication. 
Types of interventions 
Pain management interventions for patients with PAD and IC will be considered for 
inclusion. Inclusion will not be restricted to a particular form, dose, frequency, intensity, 
duration of intervention or follow up period after intervention. For many patients, the 
intervention may be complex, incorporating other interventions such as, exercise and physical 
activity, medication, nutrition, psychological interventions, social interventions, or patient 
support, in addition to the pain management. Such studies will be included as long as the 
effect of the pain management intervention can be determined.  
Types of outcome measures 
  
Primary outcome measures will include pain intensity. Secondary outcomes will be physical 
activity capacity (e.g. walking time to onset of pain, pain free walking distance, maximum 
walking time, maximal walking distance); or free living physical activity (e.g. number of 
steps taken, time spent walking, cadence/speed of walking). Both subjective and objective 
measures of physical activity will be included. Also be assessed are other clinical outcomes 
such as:  psychological outcomes (including factors such as self-efficacy, confidence, self-
esteem, social functioning and coping); patients’ perspective (responses to question on patient 
perception of interventions); quality of life. These secondary outcomes were chosen because 
they may be helpful in explaining the impact of pain outcome on physical activity 
improvement. This will enable decision regarding effective components for future designs of 
interventions. All outcome variables will be collected, analysed, graded and reported as they 
are reported in individual studies without altering the original description. 
 
Exclusion criteria 
Studies will be excluded if they were not primarily designed to target reduction of pain (even 
when pain reduction was reported), or did not explore patients’ perception of intervention 
primarily designed for pain reduction. Narrative review syntheses, systematic reviews, 
opinion papers, letters to the editor, and any study not including a primary data/or clear 
method of data analysis (determined after assessment of methodological quality), will be 
excluded. In case of duplicate publications from the same study, the most recent or most 
comprehensive publication will be included. 
 
Information search and search strategy  
A comprehensive search strategy for identifying literature relevant to this review has been 
developed and piloted (See appendix 1). This strategy was developed in accordance with the 
  
Cochrane handbook for systematic reviews of interventions [27], and the Centre for reviews 
and Dissemination recommendations for Health care review [28]. With this strategy, a search 
of bibliographic databases and grey literature will be conducted. The following databases: 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, 
Ovid MEDLINE, ProQuest health and medical complete, Allied and Complementary 
Medicine Database (AMED), Web of Science Core Collection, and Physiotherapy Evidence 
Database(PEDRO) will be searched. Also trial registers and directory of open-Access 
repository websites including http:/www.clinicaltrial.gov, http://www.opendor.org, and Web 
of science conference proceeding will be searched. Additional searches will be performed on 
relevant studies identified from reference lists. 
 
Study records and data management 
Literature search results will be exported into RefWorks
TM
 to check for duplication of 
studies, and subsequently to facilitate collaboration among reviewers during the process of 
study selection. Based on prior criteria, eligibility questions and forms for the studies 
inclusion to the two levels of eligibility assessment will then be developed, piloted, and if 
required, refined. Bibliographic records will be exported from RefWorks
TM 
into Microsoft 
excel [29], to facilitate the management selection of articles for inclusion. The review team 
will then develop, pilot, and if required, refine eligibility questions for the study inclusion 
within the review.  
 
Selection processes 
Initial screening will be conducted first on the study title and then on the abstract by one 
review author to identify potentially relevant studies. A second review author will then cross-
check these initial screening results.  Two reviewers will then read through the full length of 
  
selected titles and abstracts for further screening, using the prior eligibility criteria. Any 
difference of opinion occurring at any stage regarding inclusion or exclusion will be resolved 
by discussion and reflection, in consultation with a third reviewer if required. Study authors 
will be contacted (to the maximum of three email attempts) to clarify issues of selection of 
any study when a decision could not be made based on available information. If an author 
does not respond, the study will be excluded and the reason for exclusion recorded. Details of 
the flow of studies throughout the process of assessment of eligibility and studies selection 
will be represented along with the reasons for exclusion at each stage of the process in a flow 
chart (PRISMA diagram).  
 
Data collection Processes 
Quality appraisal for included studies 
The Mixed Methods Appraisal Tool (MMAT) [30] will be employed to assess the quality of 
included studies. The use of MMAT is to enable a valid, efficient and reliable assessment of 





tool, the studies will be assessed for the suitability of their study design to the research 
objectives, risk of bias in included studies, outcome measures, statistical issues, quality of 
reporting, intervention quality and generalizability of the study results.  
 
Two reviewers will perform the data extraction independently. Any disagreement regarding 
study eligibility will be resolved by discussion and reflection, in consultation with a third 
review author if required. The Data Extraction Template developed by the Cochrane 
Consumers and Communication Review Group [32] will be adapted to extract quantitative 
data from the quantitative studies. The Supplementary Guidance for Inclusion of Qualitative 
  
Research in Cochrane Systematic Reviews of Interventions [33] will be utilised to extract 
qualitative data from the included studies. 
 
Data items  
Data will be collected from variables including authors reference, participants’ characteristics 
(including age range, gender, inclusion and exclusion criteria), study sample size (also groups 
sample size where available), criteria used in diagnosing IC, study design, components of the 
intervention, context of intervention, who delivered the intervention, the duration of 
intervention and follow-up (where available), attrition rate, outcome(s) assessed, the 
outcome(s) measurement methods/techniques, results, and conclusions. 
 
Prioritisation of outcomes and justification 
For studies with no follow-up, the primary outcome considered will be change in pain 
following the intervention. Pain has been chosen as the primary outcomes as it may be 
relevant across diverse pain management interventions, potentially enabling a meta-analysis. 
Also, this review aims to identify factors that might raise patients’ physical activity following 
pain management interventions for IC. Decreased pain with enhanced physical activity 
translates into raised effectiveness of these pain management interventions in individuals 
with IC.  
 
Secondary outcomes will include physical activity behaviour changes post intervention; or 
adherence to physical activity behaviour changes post intervention for studies with a follow-
up period. In addition psychological health outcomes such as self-efficacy, self-esteem, social 
functioning, and quality of life will be evaluated. The secondary outcomes were selected 
because they are patients’ characteristics that may mediate effect of intervention, and hence 
  
may help in explaining the effectiveness of physical activity improvement and pain reduction. 
Only data for the first period of outcome assessment will be included for cross-over studies in 
order to avoid a cross-over effect. 
 
Risk of bias assessment in individual studies  
Using the Cochrane Collaboration Tool for Risk of Bias Assessment [27] risk of bias for each 
of the intervention studies will be evaluated in six key domains: i) selection bias (random 
sequence generation, allocation concealment); ii) performance bias (blinding - personnel and 
participants); iii) detection bias (blinding of outcome assessments); iv) bias due to attrition 
(incomplete outcome data – including drop-outs and withdrawals); v) reporting bias 
(selective reporting); and v) other bias (other sources of bias not elsewhere addressed). 
Assessment will be made in each of the included studies and graded as ‘high risk’ or ‘low 
risk’ following a well described procedure [27]. Then, summary assessment for each 
important outcome (across domains) within and across studies will be conducted [27]. When 
there is inadequate detail in a study to make a judgement, the risk of bias in that study will be 
reported as unclear. In such cases, the study authors will be contacted to provide the required 
information. Two reviewers will make judgements regarding the risk of bias independent of 
each other. Areas of differences will be resolved by discussion and reflection or in 
consultation with the third reviewer. Appraisal of the quality of the included studies will only 
be carried out after study selection has been completed, and during data extraction and 
synthesis. After this, the strength of evidence for this review will be reported.  
 
RESULTS 
The results section of this protocol reports the planned data analysis of the review. 
Data synthesis and analysis, including assessment of heterogeneity  
  
A three-phase sequential explanatory synthesis of mixed studies synthesis design will be 
employed to answer the research questions [30]. First, the question of the effectiveness of 
pain management interventions for the management of IC will be answered. In doing this, all 
quantitative studies which examined effectiveness of pain management interventions will be 
presented, compared, and pooled in an evidence table. The effectiveness of pain management 
interventions will be established by conducting a meta-analysis of the effects [30]. Data from 
quantitative studies that cannot be analysed statistically will be interpreted using narrative 
synthesis.  
 
The second phase will seek to answer question of the attitude, experiences and perspectives 
of patients to pain management interventions for IC. This will be accomplished using 
findings from all qualitative studies. In doing this, qualitative thematic analysis will be used 
to integrate the results of the qualitative studies and the qualitative results of mixed methods 
studies [30]. Interpretation of this phase will be used establish what patients perceived as 
beneficial or not beneficial.  
Lastly, interpretation of the first and second phases will be carried out to answer the overall 
objective of the systematic review of the effective components of pain management 
interventions for improving physical activity in patients with IC. The effective components of 
the interventions will be inferred by comparing the effectiveness of the interventions that 
contained the useful components identified from qualitative results with the interventions that 
did not contain these components.  
 
Characteristics of the retained studies sorted by year of publication will be presented in a 
tabular form using two different tables [34]. Table 1will describe the interventions studies 
quantitative data, while table 2 will be for the description of the qualitative studies. Table  1 
  
will have information relating to authors’ references, study designs, sample size, gender, age, 
study objectives, setting (rural vs urban), data collection format, outcomes or themes [34,35]. 
Table 2 will, in addition, have information on scales used to assess outcome, intervention 
objectives, components of the intervention, component of the control, format and provider of 
intervention, setting of intervention (home/community vs hospital), intervention and follow-
up periods, and results [34].  
 
Quantitative data analysis/Statistical analysis for Intervention studies 
Analysis and presentation of results will be made in hierarchical order with the primary 
outcomes coming before the additional outcomes. It is anticipated that there may be 
significant heterogeneity in terms of clinical characteristics of participants, diverse 
populations studied, different interventions provided, study designs, statistical strategy, and 
outcomes utilised. Hence heterogeneity will be assessed using the Cochran’s χ2 test, and 
further quantified using of I
2  
[36] in order to make decision on the effect model of meta-
analysis to use. It is expected that there will be heterogeneity that cannot readily be dealt 
with. Consequently, studies with homogenous characteristics in terms of design and 
comparator will be pooled together for meta-analysis using a random effects model [27]. 
Other heterogeneous studies will be interpreted using narrative synthesis following the 
recommendation of Centre for Reviews and Dissemination [27] to explore the relationship in 
findings between and within the included studies.  
 
In conducting meta-analysis, the statistical approach will be to compare the absolute change 
in means to the baseline (and the 95% CIs) following intervention or with change in the 
control groups where baseline data are available. Otherwise, the relative percentage change 
between post intervention values in the intervention and control groups are compared. The 
  
risk of the outcome in the intervention group will be compared with the control group, with a 
risk difference calculated from the absolute difference between the treatment and control 
groups, or the relative risk (or equivalents) for outcome measures that are dichotomous. All 
adverse effects reported in the included studies will be recoded.  All continuous outcomes 
will be assessed using the weighted mean difference or the standardized mean difference 
when different measurement scales are used to assess outcome. Skewed data and non-
quantitative data will be reported descriptively. Data analysis will use RevMan 5. 
 
Sensitivity analysis: If there are many included quantitative studies with significant 
heterogeneity in terms of intervention setting (hospital vs home/community based), design 
(RCTs vs non-RCTs), and intervention type, then subgroup analysis will be implemented to 
study the potential influence on the treatment effect directions.  This will only be conducted if 
there are more than two studies, and at least two of them are homogenous subset. Subgroup 
analysis will be limited to the primary outcomes of physical activity and pain. 
 
Publication bias/Meta-biases: To check for metabias, the funnel-plot for asymmetry and the 
Egger regression test [36] will be conducted. In doing this, data from studies published only 
as abstracts will be added to the meta-analyses to ascertain if these influenced direction of 
effect size. 
 
Qualitative data analysis  
A thematic approach will be used for synthesis of qualitative research in systematic reviews 
(Thomas and Harden [37]). This will follow a three stages process. The first stage will be free 
line-by-line coding of the findings (conclusions) of primary studies. This will be followed by 
organisation of these ‘free codes’ into related areas to construct ‘descriptive’ themes. The last 
  
stage will involve the interpretation and abstraction of the descriptive themes to develop 
higher order explanations. Synthesis from conclusion/findings, instead of from data, is 
preferred to enable different qualitative research methods to be combined in a single 
synthesis of qualitative studies. The review team will validate each of these stages of 
qualitative analysis by comparing the generated codes and themes with the 
conclusions/findings of the primary studies. 
 
Rating quality of evidence and strength of recommendations 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) will 
be used to judge the quality of evidence of the studies to determine the strength of 
recommendations in the systematic review, following the approach published by Guyatt et al 
[38].  Each study will be assessed for study limitations, inconsistency of results, indirectness 
of evidence, imprecision, and reporting bias. Each study will be rated as high risk of bias or 
low risk of bias (alternatively a high quality study or a low quality study). Each evidence 
statement for this review will then be graded from ‘High Quality’ to ‘Very Low Quality’ 
according to the criteria in Table 1 below.  
 
Table 1: Quality of evidence and definitions adapted from Guyatt et al [38] 
High Quality Evidence derived from many studies of high quality such that further research 
is very unlikely to change our confidence in the estimate of effect  
Moderate Quality Evidence derived from mostly studies of moderate quality and/or few high 
quality studies such that further research is likely to have an important 
impact on our confidence in the estimate of effect and may change the 
estimate 
Low Quality  Evidence derived from mostly low quality studies and/or few studies of 
moderate quality such that further research is very likely to have an 
important impact on our confidence in the estimate of effect and is likely 
to change the estimate 
Very Low Quality  All evidence derived from studies of low quality studies such that any 
estimate of effect is very uncertain 
 
  
How this review will be reported 
This systematic review will be reported according to the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) Statement [39], with all items relevant to 
the review included in the report. A PRISMA checklist applicable to this review will be 
published with the final report.  
Dealing with protocol amendments during the review and after review 
In order to avoid the introduction of outcome reporting bias, amendments will not be made on 
the quantitative aspect of this review protocol based on the findings from the included 
studies. This precaution is taken because quantitative studies are more easily influenced by 
publication bias and the manifestations of these biases are more easily assessed.  However, 
any justified unanticipated amendment, possibly arising from a clearer understanding of the 
review questions, will be documented and implemented by the first author. In the event of 
this amendment, the report of the review findings, distinction will be made between the initial 
review question(s) and any subsequent amendment(s) in the report of the review. 
 
DISCUSSION 
IC from PAD of the lower extremity is a debilitating condition affecting a range of walking 
ability, health status and the quality of life of patients [2-4]. Management interventions that 
target walking limiting pain in this group will be potentially valuable in increasing an 
individuals’ capacity to engage in physical activity. This systematic review will provide 
evidence in support or against the hypothesis that interventions with a pain management 
component can be effective for individuals with IC.  This conclusion will be derived from a 
synthesis of the quantitative measurement of pain and physical activity outcomes following 
pain management interventions and qualitative evidence regarding the effectiveness and 
patient compliance with pain management interventions.  When conducted, the ability of the 
  
review to comment definitively on the topic will be limited by the quantity and quality of 
available evidence.  However overall, the review will clarify the existing evidence base 
regarding the effect of pain management interventions on physical activity, and allow the 
selection of effective components of pain management for future tailored intervention. 
 
Protocol registration: This review was registered with the International Prospective Register 
of Systematic Reviews (PROSPERO) on 04 November 2015 (registration number: 
CRD42015027912). 
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Appendix 1: Search strategy 
 
AMED(EBSCO host)Searched 05/01/2016 
S28 S10 AND S19 AND S28 
S28 S20 OR S21 S22 OR S23 OR S24 OR S25 OR S26 OR S27 
S27 treadmill walking 
S26 walking ability  
S25 time spent walking 
S24  claudication distance 
S23 walking distance 
S22 physical capacity 
S21 physical activity capacity 
S20 Physical activity 
S19 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR 17 OR S18 
S18 transcutaneous electrical stimulation 
S17 transcutaneous electric nerve stimulation 
S16 transcutaneous electrical nerve stimulation 
S15 transcutaneous electrical nerve stimulation (tens) 
S14 pain control 
S13 pain management 
S12 pain medication  
S11 pain management interventions  
S10 S9 OR S8 OR S7 OR S6 OR S5 OR S4 OR S3 OR S2 OR S1 
S9 ischemic lower extremity disease 
S8 peripheral arterial occlusive diseases 
S7 peripheral arterial diseases (pad) of lower extremities 
S6  peripheral vascular diseases 
S5  peripheral arterial diseases 
S4 intermittent claudication symptoms 
S3  intermittent claudication 
S2 claudicants  
S1 arterial occlusive diseases 
 
PsycINFO (ProQuest host) (1955-2015 Nov). Searched 02/01/2016 
("intermittent claudication" OR "claudicants") AND ("pain management” OR "pain 
management intervention" OR "pain medication" OR "pain chemotherapy") OR 
("transcutaneous electric nerve stimulation" OR “transcutaneous electrical nerve stimulation" 
OR "effect of transcutaneous electrical nerve stimulation" OR "transcutaneous nerve 
stimulation") AND ("physical activity” OR "walking"  OR "physical activity capacity" OR 
"walking capacity") OR ("walking distance" OR "claudication distance" OR "time spent 
walking") 
 
ProQuest Research Library. Searched 04/01/2016 
("intermittent claudication" OR claudicants) AND ("pain management" OR "pain 
management intervention" OR "transcutaneous electrical nerve stimulation” OR 
"transcutaneous electric nerve stimulation") AND ("physical activity” OR "physical activity 
capacity" OR "walking capacity" OR "functional capacity") OR ("walking distance” OR 
"claudication distance”) 
 
PEDro database Searched  01/01/2016 
  
1. Intermittent claudication* pain management* physical activity* 
2. Ischemic leg pain* pain therapy* physical activity 
3. Intermittent claudication* transcutaneous electrical nerve stimulation* physical 
function* 
4. Intermittent claudication* transcutaneous electrical nerve stimulation* physical 
activity* 
5. Intermittent claudication* transcutaneous electrical nerve stimulation* walking 
distance* 
 
ScienceDirect Searched 03/01/2016 
"intermittent claudication" OR claudicants AND "pain management" OR "pain management 
intervention" OR "transcutaneous electrical nerve stimulation"  OR "transcutaneous electric 
nerve stimulation" OR anaesthesia” AND "physical activity"  OR "claudication distance" OR 
"physical activity capacity" OR "walking capacity" OR "functional capacity" OR "walking 
distance"  
 
Ovid® Searched 06/01/2016 
16 4 AND 8 AND 15 
15 9 OR 10 OR 11OR 12 OR 13 OR 14 
14 claudication distance. mp. 
13 exp walking/ OR walking distance.mp 
12 walking distance.mp 
11 walking capacity.mp 
10 Exercise tolerance/OR physical capacity.mp 
9 physical activity.MP. OR exp motor activity/ 
8  5 OR 6 OR 7 
7  transcutaneous electrical nerve stimulation.mp 
6 exp transcutanous electrical nerve stimulation.mp 
5 exp pain management/ OR pain management intervention*.mp. 
4 1 OR 2 OR 3 
3  exp peripheral arterial diseases/or exp peripheral vascular diseases/ OR exp arterial 
occlusive diseases/ 
2 claudicant*. Mp 
1 intermittent claudication.mp. OR exp intermittent claudication 
 
CINAHL Searched 03/01/2016 
S23 S4 AND S12 AND S22 
S22 S13 S14 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 
S21 ”Treadmill walking” 
S20 “Walking ability” 
S19 “Claudication index”  
S18 “Time spent walking” 
S17 “Claudication distance” 
S16 MH “Walking+”) OR “walking distance” 
S15 “physical activity capacity” 
S14 “walking capacity” 
S13 (MH “physical activity”) 
S12 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11  
S11 “transcutaneous electrical nerve stimulation” 
S10 “pain medication” 
  
S9 “pain management” 
S8 (MH “transcutaneous electrical nerve stimulation (Iowa NIC)”) OR (MH 
“transcutaneous electric nerve stimulation”) 
S7 (MH “anagelsia”) 
S6 (MH “pain control”(Saba CCC)”) 
S5  (MH “pain management (Iowa NIC)”) 
S4 S1 OR S2 OR S3 
S3 (MH “peripheral arterial diseases”) 
S2 (MH “intermittent claudication”) 
S1 (MH “arterial occlusive diseases”) (MH “peripheral vascular diseases”)  
 
MEDLINE®(ProQuest host)04/01/2016 
(intermittent claudication) OR (vascular claudication OR claudicants) AND (transcutaneous 
electric nerve stimulation OR transcutaneous electric nerve stimulation) OR (pain 
management interventions OR pain relief) OR (pain medication OR pain management) AND 
(physical activity OR physical activity capacity) OR (walking capacity OR walking distance) 
OR (claudication distance OR walking ability) OR (time spent walking) 
 
ISI Web of ScienceSearched 07/01/2016 
1. (Intermittent claudication* or peripheral arterial occlusion* or peripheral arterial 
disease* or peripheral vascular claudication*)  
2. (pain management* or intervention* or trial* or effect* or efficacy* or effectiveness* 
or pain management or pain medication* transcutaneous electrical nerve stimulation* 
transcutaneous electric nerve stimulation* transcutaneous electrical stimulation* 
peripheral vascular disease education* health education*)  
3. (control group* or medical intervention* or other intervention* or usual care*) 
4. (physical activity* claudication distance* or physical activity capacity* or walking 
ability* or walking distance) 
5. #1 AND #2 AND #3 AND #4(Intervention studies) 
6. #1 AND #2 AND #3 AND #4(Qualitative studies) 
7. #1 AND #2 AND #3 AND #4(Observational studies) 
 
 
 
